NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Achieve Life Sciences, Inc. (ACHV) Stock Analysis

Achieve Life Sciences, Inc. (ACHV) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ACHV

$8.49

+$0.18 (+2.17%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ACHV with… →

ACHV Key Statistics

As of Sep 4, 2026
Trading
Open
$8.20
Previous Close
$8.31
Day's Range
8.10–8.56
52-Week Range
2.62–8.64
Volume
874.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.25
Valuation
Market Cap
$873.64M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
17.68
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.70
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$54.65M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
102.90M
1-Year Return
+204.30%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
1.82M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ACHV Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+70.82%
2025+41.19%
2024−14.56%
2023+68.16%
2022−68.51%
2021−3.95%
2020−23.58%
2019−56.20%
2018−90.97%
2017−75.64%
2016 (partial year)−43.82%

As of September 4, 2026.

ACHV Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$54.65M—
2024$0.00−$39.83M—
2023$0.00−$29.82M—
2022$0.00−$42.35M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$54.88M−$54.65M—
2024$0.00—−$39.07M−$39.83M—
2023$0.00—−$27.25M−$29.82M—
2022$0.00—−$40.80M−$42.35M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ACHV Valuation vs Biotechnology Median

Median of 656 stocks
MetricACHVBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Achieve Life Sciences, Inc. (ACHV) is capitalised at $873.64M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 28 employees.

ACHV last closed at $8.49 on September 4, 2026. That is +$0.18 (+2.17%) against the previous close. The 52-week range on file runs from $2.62 to $8.64. The latest close sits 224.05% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $54.65M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −1.7.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The PEG ratio, which sets the P/E against expected earnings growth, reads 17.68.

Beta against the wider market is reported at 2.25. Annualized volatility over the trailing 10 years is 90.69%. The trailing one-year price return is +204.30%. Measured over 10 years, that is −38.87% a year compounded.

Growth & Income

The record shows no dividend for ACHV.

Across the complete calendar years on file, 2023 returned +68.16% and 2018 returned −90.97%. Of the 9 complete calendar years on file, 2 finished higher. 2026 is still running; the price is +70.82% year to date.

Peer Comparison

Achieve Life Sciences, Inc. (ACHV) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Achieve Life Sciences, Inc. ACHV $873.64M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Achieve Life Sciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Achieve Life Sciences, Inc.

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.

Visit website →